Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Asian Pac J Cancer Prev ; 25(1): 87-94, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38285771

ABSTRACT

BACKGROUND AND AIMS: Being one of the most common cancers accounting for approximately 185 million cases globally, colorectal cancer (CRC) is one of the leading derivers of cancer-related mortalities. A high prevalence of Type 2 diabetes mellitus and CRC was noted, together with a causal link between diabetes and CRC development. Thereby, the goal of this study was to properly evaluate type 2 Diabetes mellitus in non-metastatic colorectal cancer patients, and to highlight its impacts on patient's outcome. METHODS: Patients with non-metastatic colorectal cancer diagnosed between January 2016 and December 2020 were studied retrospectively. Patients were divided into two groups based on whether or not they had type II diabetes. The clinico-pathological, laboratory, treatment and survival data were gathered. RESULTS: A total of 318 patients were included in this study. The toxicity of the drugs used in CRC patients receiving the treatment protocols (169 in non-T2DM group and 39 in T2DM group), both groups reported close percentage of side effects and  a similar frequency of drug toxicity occurrence as well as grade of toxicity, with the exception of neuropathy, which was more common in the T2DM group (33.3% vs 11.2%). As for prognosis, non-T2DM and T2DM patients had a mean progression free survival of (71.4 and 60.83 months, respectively) (p = 0.019). Overall survival was 73.1% for T2DM and 85.3% for non T2DM cases. The median overall survival was not reached for both groups in terms of overall survival. CONCLUSION: T2DM is considered a risk factor for poor survival among CRC patients. Treatment related toxicity is not affected by the presence or absence of diabetes, yet neuropathy needs further studies for diabetic patients receiving oxaliplatin.


Subject(s)
Colorectal Neoplasms , Diabetes Mellitus, Type 2 , Humans , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Retrospective Studies , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/diagnosis , Risk Factors , Oxaliplatin/adverse effects
2.
Med Res Rev ; 42(1): 183-226, 2022 01.
Article in English | MEDLINE | ID: mdl-33945158

ABSTRACT

Two decades of research have proven the relevance of ion channel expression for tumor progression in virtually every indication, and it has become clear that inhibition of specific ion channels will eventually become part of the oncology therapeutic arsenal. However, ion channels play relevant roles in all aspects of physiology, and specificity for the tumor tissue remains a challenge to avoid undesired effects. Eag1 (KV 10.1) is a voltage-gated potassium channel whose expression is very restricted in healthy tissues outside of the brain, while it is overexpressed in 70% of human tumors. Inhibition of Eag1 reduces tumor growth, but the search for potent inhibitors for tumor therapy suffers from the structural similarities with the cardiac HERG channel, a major off-target. Existing inhibitors show low specificity between the two channels, and screenings for Eag1 binders are prone to enrichment in compounds that also bind HERG. Rational drug design requires knowledge of the structure of the target and the understanding of structure-function relationships. Recent studies have shown subtle structural differences between Eag1 and HERG channels with profound functional impact. Thus, although both targets' structure is likely too similar to identify leads that exclusively bind to one of the channels, the structural information combined with the new knowledge of the functional relevance of particular residues or areas suggests the possibility of selective targeting of Eag1 in cancer therapies. Further development of selective Eag1 inhibitors can lead to first-in-class compounds for the treatment of different cancers.


Subject(s)
Ether-A-Go-Go Potassium Channels , Neoplasms , Ether-A-Go-Go Potassium Channels/metabolism , Humans , Neoplasms/drug therapy
3.
Eur J Drug Metab Pharmacokinet ; 45(3): 351-360, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31997084

ABSTRACT

BACKGROUND AND OBJECTIVES: Green tea catechins were recently reported to inhibit drug transporters such as organic anion-transporting polypeptides (OATPs) and metabolic enzymes, affecting the bioavailability of many drugs. This study aimed to evaluate the clinical significance of the effects of different doses of green tea extract on the pharmacokinetic parameters of atorvastatin and to rationalize the associated interaction mechanism. METHODS: A randomized, double-blind, three-phase crossover study involving 12 healthy volunteers was performed. Participants received a single dose of atorvastatin 40 mg alone (control group), atorvastatin 40 mg plus a capsule containing 300 mg of dry green tea extract, or atorvastatin 40 mg plus a capsule containing 600 mg of dry green tea extract. Plasma samples taken from the volunteers were analyzed for atorvastatin using liquid chromatography-tandom mass spectrometry (LC/MS/MS). RESULTS: Compared to atorvastatin alone, the administration of 300 mg or 600 mg of the green tea extract along with atorvastatin decreased the peak plasma concentration (Cmax) of atorvastatin by 25% and 24%, respectively (P < 0.05), and the area under the plasma concentration-time curve (AUC0-∞) of atorvastatin by 24% and 22%, respectively (P < 0.05). Additionally, administration of 300 mg or 600 mg of the green tea extract increased the apparent oral clearance (CL/F) of atorvastatin by 31% and 29%, respectively. The time to Cmax (Tmax) and the elimination half-life (t1/2) of atorvastatin did not differ among the three phases. The effects of 600 mg of the green tea extract on the pharmacokinetic parameters of atorvastatin were not significantly different from the effects of 300 mg of the green tea extract. CONCLUSION: Green tea extract decreases the absorption but not the elimination of atorvastatin, possibly by inhibiting OATP, albeit not in a dose-dependent manner. Coadministration of green tea extract with atorvastatin may necessitate the monitoring of the plasma concentration of atorvastatin in clinical practice.


Subject(s)
Atorvastatin/pharmacokinetics , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Plant Extracts/pharmacology , Tea/chemistry , Adult , Area Under Curve , Catechin/pharmacology , Chromatography, Liquid , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Herb-Drug Interactions , Humans , Male , Middle Aged , Organic Anion Transporters/antagonists & inhibitors , Plant Extracts/administration & dosage , Tandem Mass Spectrometry , Young Adult
4.
Pain ; 160(2): 508-527, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30335684

ABSTRACT

Sensitization of the transient receptor potential ion channel vanilloid 1 (TRPV1) is critically involved in inflammatory pain. To date, manifold signaling cascades have been shown to converge onto TRPV1 and enhance its sensitization. However, many of them also play a role for nociceptive pain, which limits their utility as targets for therapeutic intervention. Here, we show that the vesicle transport through interaction with t-SNAREs homolog 1B (Vti1b) protein promotes TRPV1 sensitization upon inflammation in cell culture but leaves normal functioning of TRPV1 intact. Importantly, the effect of Vti1b can be recapitulated in vivo: Virus-mediated knockdown of Vti1b in sensory neurons attenuated thermal hypersensitivity during inflammatory pain without affecting mechanical hypersensitivity or capsaicin-induced nociceptive pain. Interestingly, TRPV1 and Vti1b are localized in close vicinity as indicated by proximity ligation assays and are likely to bind to each other, either directly or indirectly, as suggested by coimmunoprecipitations. Moreover, using a mass spectrometry-based quantitative interactomics approach, we show that Vti1b is less abundant in TRPV1 protein complexes during inflammatory conditions compared with controls. Alongside, we identify numerous novel and pain state-dependent binding partners of native TRPV1 in dorsal root ganglia. These data represent a unique resource on the dynamics of the TRPV1 interactome and facilitate mechanistic insights into TRPV1 regulation. We propose that inflammation-related differences in the TRPV1 interactome identified here could be exploited to specifically target inflammatory pain in the future.


Subject(s)
Gene Expression Regulation/genetics , Hyperalgesia/genetics , Pain/metabolism , Qb-SNARE Proteins/metabolism , TRPV Cation Channels/metabolism , Animals , Calcium/metabolism , Capsaicin/pharmacology , Cells, Cultured , Disease Models, Animal , Freund's Adjuvant/toxicity , Ganglia, Spinal/cytology , Humans , Hyperalgesia/physiopathology , Inflammation/chemically induced , Inflammation/complications , Mice , Mice, Inbred C57BL , Mice, Transgenic , Pain/etiology , Qb-SNARE Proteins/genetics , RNA Interference/physiology , Sensory Receptor Cells/drug effects , Sensory Receptor Cells/physiology , Signal Transduction , TRPV Cation Channels/genetics
5.
J Contemp Dent Pract ; 19(10): 1181-1188, 2018 Oct 01.
Article in English | MEDLINE | ID: mdl-30498172

ABSTRACT

AIM: To compare the effect of nano-hydroxyapatite (9000 ppm F) and casein phosphopeptide-amorphous calcium phosphate fluoride (900 ppm F) pastes on initial enamel carious lesions of young permanent teeth. MATERIALS AND METHODS: Sixty extracted young premolars with a standardized window on enamel were immersed in a demineralizing solution for 48 hours to produce subsurface enamel lesions. They were divided into three groups according to remineralizing agents (n = 20) group I: nano-hydroxyapatite paste; group II: casein phosphopeptide-amorphous calcium phosphate fluoride paste; and group III: control (without an agent). The enamel surface microhardness (SMH) was measured at baseline, after the incipient enamel lesion, and after treatment. Additional twenty young premolars were selected and prepared as mentioned above for surface morphology evaluation by scanning electron microscope (SEM). RESULTS: No significant difference was found in mean surface microhardness in teeth treated with nano-hydroxyapatite paste and those treated with casein phosphopeptide-amorphous calcium phosphate fluoride p = 0.26. SEM showed improvement in surface defects of demineralized enamel in the two test groups. CONCLUSION: Nano-hydroxyapatite and casein phosphopeptide-amorphous calcium phosphate fluoride pastes were effec -tive in rehardening the initial enamel caries lesions in young permanent teeth. CLINICAL SIGNIFICANCE: The best strategy for caries management is to focus on the methods of improving the reminer-alization process with the aid of the remineralizing agents. The current study compared the remineralizing effect of two remineralizing agents. Within the limitations of the study, both remineralizing agents were effective for remineralization of early caries-like lesions.


Subject(s)
Bicuspid/physiology , Caseins/pharmacology , Collagen/pharmacology , Dental Enamel/physiology , Durapatite/pharmacology , Tooth Calcification/drug effects , Tooth Remineralization/methods , Caseins/administration & dosage , Collagen/administration & dosage , Dental Caries/physiopathology , Dental Enamel/drug effects , Dental Enamel/ultrastructure , Durapatite/administration & dosage , Hardness , Humans , In Vitro Techniques , Microscopy, Electron, Scanning , Ointments , Surface Properties
SELECTION OF CITATIONS
SEARCH DETAIL
...